SCHEMBL254913

SCHEMBL254913

NC(=O)Cc1cccc(-c2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.54
AOC3 Q16853 3/20 0.54
AGXT P21549 1/20 0.52
NPC1 O15118 1/20 0.51
HPGD P15428 1/20 0.51
NFKB1 P19838 1/20 0.51
STAT1 P42224 1/20 0.51
RAB9A P51151 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
GGPS1 O95749 2/20 0.50
FAAH O00519 1/20 0.50
NAAA Q02083 1/20 0.50
CFD P00746 2/20 0.49
PLA2G10 O15496 1/20 0.49
PLA2G2A P14555 1/20 0.49
BCL2 P10415 1/20 0.49
PLG P00747 1/20 0.48
PLAU P00749 1/20 0.48
F11 P03951 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7265237 0.86 RORC (0.44) RORCAOC3AGXTNPC1HPGD
SCHEMBL3437800 0.84 AOC3 (0.53) AOC3AGXTGGPS1FAAHNAAA
SCHEMBL538397 0.84 ABCC4 (0.67) AOC3FAAHNAAAPLA2G10PLA2G2A
SCHEMBL15782613 0.84 ICMT (0.55)
SCHEMBL10339219 0.83 CA2 (0.54) NPC1HPGDNFKB1STAT1RAB9A
SCHEMBL12607534 0.83 DRD1 (0.47) RORCAOC3NPC1HPGDNFKB1
SCHEMBL12550972 0.82 LMNA (0.53) AOC3AGXTGGPS1FAAHNAAA
SCHEMBL31725439 0.82 AOC3 (0.51) AOC3AGXTGGPS1FAAHNAAA
SCHEMBL1395755 0.82 LMNA (0.69) NPC1HPGDNFKB1STAT1RAB9A
SCHEMBL28032595 0.82 LMNA (0.63) AOC3HPGDNFKB1FAAHNAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024259171-A2 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2024-12-19 WO disclosed
WO-2019075394-A1 COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME VANDERKLISH PETER (US) 2019-04-18 WO disclosed
EP-2558085-B1 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER ATHENEX INC (US) 2017-08-30 EP disclosed
EP-2499148-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2017-01-18 EP disclosed
CN-103958500-A Protein kinase inhibitors ORION CORP 2014-07-30 CN disclosed
WO-2011129936-A9 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER KINEX PHARMACEUTICALS, LLC (US) 2012-03-08 WO disclosed
WO-2011129936-A2 COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER KINEX PHARMACEUTICALS, LLC (US) 2011-10-20 WO disclosed
EP-1435934-A1 5'-ACYLAMINO-1,1'-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-07-14 EP disclosed
WO-2003032971-A1 5’-ACYLAMINO-1,1’-BIPHENYL-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-04-24 WO disclosed